Webinar: Results from ACTG 5279/BRIEF-TB trial
Have you heard?? ACTG 5279: One-month TB prophylaxis as effective as nine-month regimen for people living with HIV
Community Partners and the Community Research Advisors Group
(CRAG) will host a webinar on 10 July 2018 to present results
from the ACTG 5279/BRIEF-TB trial, a phase III study that
evaluated the safety and efficacy of a one-month regimen for
preventing TB (1HP) in people with HIV.
The study
favorably compared 1HP (which involves taking rifapentine and
isoniazid daily for one month) to the longer 9-month regimen of
daily isoniazid (isoniazid preventive therapy or IPT).
This is a landmark study that promises to shorten
preventive therapy for people with HIV and improve its
acceptability. The principal investigators of the study will
present the trial results and discuss implications for the
field. There will also be a discussion of how activists and
community members can work to improve the availability,
accessibility, and affordability of the regimen.
For
more information about the webinar and to register, click
here.
